<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04888247</url>
  </required_header>
  <id_info>
    <org_study_id>HL-2021-01</org_study_id>
    <nct_id>NCT04888247</nct_id>
  </id_info>
  <brief_title>HighFLO Study - HighLife Trans-septal Mitral Valve Replacement (TSMVR) Feasibility Study of the Open Cell CLARITY Valve</brief_title>
  <acronym>HighFLO</acronym>
  <official_title>HighLife TSMVR Feasibility Study of the Open Cell CLARITY Valve in Patients With Moderate-severe or Severe MR, High Surgical Risk and With a High Risk for Left Ventricular Outflow Tract Obstruction (LVOTO)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HighLife SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>HighLife SAS</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Feasibility, safety and performance of the HighLife CLARITY TSMV and its delivery system&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study to assess the feasibility, safety, and performance of the HighLife CLARITY TSMV, and&#xD;
      its deliver systems, in NYHA Class ≥ II-IV patients with moderate-severe or severe mitral&#xD;
      regurgitation who are at high risk for surgical treatment according to the local&#xD;
      multidisciplinary Heart Team decision, and who are at high risk for potential LVOT&#xD;
      obstruction(LVOTO).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of subjects meeting Technical Success</measure>
    <time_frame>24 hours</time_frame>
    <description>Successful vascular access, delivery and retrieval of the HighLife delivery systems&#xD;
Deployment and correct positioning of the HighLife 28mm CLARITY TSMV&#xD;
Freedom from additional emergency surgery or re-intervention related to the device or access procedure, that occurred (was initiated) during the procedure. Any emergency surgery or re-intervention that occurs after the patient exits the procedure room/cath lab in stable condition will be captured as an AE/SAE&#xD;
Successful vascular access, delivery and retrieval of the HighLife delivery systems&#xD;
Deployment and correct positioning of the HighLife 28mm CLARITY TSMV&#xD;
Freedom from additional emergency surgery or re-intervention related to the device or access procedure, that occurred (was initiated) during the procedure. Any emergency surgery or re-intervention that occurs after the patient exits the procedure room/cath lab in stable condition will be captured as an AE/SAE</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Mitral Regurgitation</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trans-septal mitral valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CLARITY</intervention_name>
    <description>Trans-septal mitral valve replacement</description>
    <arm_group_label>Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Moderate-severe or severe mitral regurgitation (≥ 3+)&#xD;
&#xD;
          3. Patient has New York Heart Association (NYHA) Functional Class II, III or ambulatory&#xD;
             IV&#xD;
&#xD;
          4. Patient is under guideline directed medical therapy for at least one month, as&#xD;
             reviewed and confirmed by the local multidisciplinary Heart Team&#xD;
&#xD;
          5. Patient is high-risk for open-heart surgery based on the assessment of the&#xD;
             multidisciplinary Heart Team using standard scoring systems and consideration of&#xD;
             co-morbidities, frailty, and disability&#xD;
&#xD;
          6. Patient meets the anatomical criteria for HighLife valve&#xD;
&#xD;
          7. Patient is willing to participate in the study and provides signed informed consent&#xD;
&#xD;
          8. Patients with a high risk for LVOTO&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any stroke/TIA within 30 days&#xD;
&#xD;
          2. Severe symptomatic carotid stenosis (&gt; 70% by non-invasive imaging)&#xD;
&#xD;
          3. Active infections requiring antibiotic therapy&#xD;
&#xD;
          4. Active ulcer or gastro-intestinal bleeding in the past 3 months&#xD;
&#xD;
          5. History of bleeding diathesis, coagulopathy or refusal of future blood transfusion&#xD;
&#xD;
          6. Patients in whom TEE is not feasible&#xD;
&#xD;
          7. Patients who are pregnant or lactating, or plan to get pregnant in the next 12 months.&#xD;
&#xD;
          8. Patient is unable to comply with the follow-up schedule and assessments&#xD;
&#xD;
          9. Participation in another clinical investigation at the time of inclusion&#xD;
&#xD;
         10. Patient has known allergies to the device components or contrast medium&#xD;
&#xD;
         11. Patient cannot tolerate anticoagulation or antiplatelet therapy&#xD;
&#xD;
         12. Patients with a life expectancy of less than 12 months due to non-cardiac conditions&#xD;
&#xD;
         13. Patient had permanent pacemaker, or similar device with implantable cardiac leads&#xD;
             (i.e. resynchronization therapy) within the last 3 months&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cliniue Pasteur</name>
      <address>
        <city>Toulouse</city>
        <zip>31076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier Tchetche</last_name>
      <phone>+33562211699</phone>
      <email>dtchetche@clinique-pasteur.com</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 4, 2021</study_first_submitted>
  <study_first_submitted_qc>May 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitral Valve Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

